Pretherapeutic prognostic factors for survival under chemoimmunotherapy/immunotherapy of advanced NSCLC patients
A detailed prognostic factor analysis for overall survival and progression-free survival in selected groups of advanced non-small-cell lung cancer patients under chemo- or mono-immunotherapy identified five independent parameters: initial ECOG of zero, non-elevated LDH, non-elevated CRP, pretreatment PD-L1 positivity and absence of KEAP1-mutation. Our findings are especially helpful of estimating early treatment failure with aggressive lung cancer progression. This important investigation will be prospectively confirmed in a larger, more unselected population at our Cancer Centre.
Authors
- Martin Metzenmacher (ORCID: https://orcid.org/0000-0001-5395-9010)
- D. Theegarten
- J. Hense (ORCID: https://orcid.org/0000-0003-4679-2026)
- M. Wiesweg
- Martin Schüler (ORCID: https://orcid.org/0000-0002-2166-3394)
- Nika Guberina
- Servet Bölükbas (ORCID: https://orcid.org/0000-0001-8275-5957)
- Gregor Zaun (ORCID: https://orcid.org/0000-0002-3813-6961)
- Martin Stuschke (ORCID: https://orcid.org/0000-0001-6836-0940)
- Filiz Öezkan (ORCID: https://orcid.org/0000-0002-9398-1260)
- Julija Judickiene
- Wilfried E.E. Eberhardt
- Elisabeth. D Meschke
Institutions
- German Cancer Research Center (DE)
- Ruhrlandklinik (DE)
- West Cancer Center (US)
- German Marine Research Consortium (DE)
- West German Heart and Vascular Center Essen (DE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1016/j.ejca.2026.116600
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00